Bio-Techne Announces Commercial Availability Of GMP-Grade Proteins From Dedicated GMP Facility

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced the commercial launch of GMP-grade proteins from its new St. Paul, MN facility, focusing on large-scale production for cell and gene therapy workflows. This investment of $50 million enhances its capacity to meet the increasing demand driven by over 1300 ongoing clinical trials in cell therapy, marking a 43% increase from the previous year. The facility's state-of-the-art technology and scalability aim to ensure lot-to-lot consistency and patient safety in GMP manufacturing.

Positive

• Investment of $50 million in a new GMP-grade protein manufacturing facility.
• Facility supports large-scale production to meet increasing demand in cell and gene therapy.
• The facility enhances lot-to-lot consistency and GMP process capabilities, ensuring patient safety.

Negative

• None.

MINNEAPOLIS, Nov. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the commercial availability of GMP-grade materials manufactured at  its St. Paul, MN GMP (Good Manufacturing Practices) manufacturing facility. The facility is dedicated to supporting large-scale production of GMP-grade proteins, including animal-free cytokines and growth factors, that are essential components of cell culture media for immuno-oncology, regenerative medicine and gene-modified cell therapy workflows. Cell therapies are rapidly growing fields of medicine that introduce living cells into patients to treat disease or repair damaged tissue functions. These next generation treatments show remarkable promise and represent new hope where traditional therapies may have failed.

As described in a recent article in Nature, in 2021 there were more than 1300 ongoing cell therapy clinical trials worldwide, an increase of 43% over the previous year. The rapidly growing number of trials and ultimate push toward commercialization has resulted in an increasing need for larger quantities of GMP-grade animal free proteins used in clinical manufacturing. For Bio-Techne and its new facility, this means large-scale production of proteins with lot-to-lot consistency, GMP process capabilities for patient safety, and the scalability necessary to support large clinical trials and future successful therapeutics. Bio-Techne invested approximately $50 million to build the new facility and has equipped it with state-of-the-art manufacturing and quality control technologies. With multiple fermenters, purification suites, and room for future expansion, the new facility places Bio-Techne in an excellent position to meet anticipated future demand.

 "Bio-Techne is the global leader in research-grade proteins and has experienced rapid recent growth in GMP-grade proteins," commented Chuck Kummeth, Bio-Techne's President and Chief Executive Officer. "Our new facility gives us  the scalability and capacity to bring our GMP-grade protein business to the next level, providing a reliable source of the highest quality proteins to support the rapidly growing cell and gene therapy market. It's been exciting to watch our site in St. Paul, MN successfully complete the qualification process and we look forward to playing our part in the world's most innovative science and medicine."

More information on Bio-Techne's portfolio of products for Cell & Gene Therapy workflow can be found at www.bio-techne.com/research-areas/cell-and-gene-therapy.

About Bio-Techne Corporation (NASDAQ:TECH)

Contact: David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-commercial-availability-of-gmp-grade-proteins-from-dedicated-gmp-facility-301415000.html

SOURCE Bio-Techne Corporation

FAQ

What recent announcement did Bio-Techne (NASDAQ: TECH) make regarding GMP-grade proteins?

Bio-Techne announced the commercial availability of GMP-grade proteins from its new manufacturing facility in St. Paul, MN.

How much did Bio-Techne invest in its new GMP manufacturing facility?

Bio-Techne invested approximately $50 million to build the new GMP manufacturing facility.

How many clinical trials are currently ongoing in cell therapy as of 2021?

As of 2021, there are more than 1300 ongoing clinical trials in cell therapy worldwide, a 43% increase from the previous year.

What capacities does the new facility provide for Bio-Techne (NASDAQ: TECH)?

The new facility provides scalability and capacity to support large clinical trials and future therapeutics in cell and gene therapy.